Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT04354246

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
110 (estimated)
Sponsor
Compugen Ltd · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

Conditions

Interventions

TypeNameDescription
DRUGDose escalation: COM902 monotherapy.COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
COMBINATION_PRODUCTEvaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.
DRUGCohort expansion: COM902 (RDFE) monotherapy.COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
DRUGCohort expansion: COM902 in combination with COM701 (both at the RDFE).COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
COMBINATION_PRODUCTCohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.

Timeline

Start date
2020-03-31
Primary completion
2025-12-30
Completion
2025-12-30
First posted
2020-04-21
Last updated
2025-05-22

Locations

9 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04354246. Inclusion in this directory is not an endorsement.